iPill Dispenser

A digital health - hardware Innovation to improve prescription adherence and safety by reducing opioid diversion and abuse



John Hsu MD John@iPillDispenser.com 626-695-5985

The Problem The Child-Resistant cap no longer protects children from drug overdoses



The Child-Resistant cap was never meant to protect adults; More than 49,600 adults died of a drug overdose in 2016



Drug overdoses in children rose 268.2% between 1999-2016

3.3 BILLION unused opioids and 9 million stolen opioid units flood our communities every year for diversion and abuse

The Result

- Too many unused opioids
- No Control of Dispensing
- No Secure Storage
- No Safe Disposal
- No Monitoring

The Solution – the iPill Dispenser



- Improved Safety :
- Prescription Adherence
- Secure storage safe disposal for opioid drugs
- Tamper resistant design
 - Contained pills destroyed if tampered
 - Unused pills automatically destroyed at 90 days

- Reduced Costs :
- Prescription Adherence
- Reduction of loss of workers' productivity
- Reduction of insurers' member costs from opioid abuse and addiction
- Reduction of opioid overdoses and death

Why Now?

We have no effective solution.

• Ever increasing child and adult overdoses.

- Ever increasing Heroin and Fentanyl overdoses.
- Government Policy has not been effective.
- Narcan is for those already overdosed.
- Suboxone is for people already addicted.



FDA is looking for a solution.

- The iPill Dispenser was named a winner of 2018
 FDA Innovation Challenge for the Treatment and Prevention of Opioid Use Disorder .
- The iPill Dispenser was designated a 2018 "breakthrough" innovation medical device by the FDA.
- The iPill was then designated for the de novo FDA approval path.



iPill. 5 year Forecast Market Potential

Year	TAM*	# of Expected Units (SOM"")	Gross Revenue
1	18 million	92,000	\$5 million
2	20 million	147,000	\$9 million
3	22 million	282,000	\$17 million
4	24 million	543,000	\$32 million
5	26 million	1,045,000	\$62 million

- ✤ Assumptions: Growth rate of prescription is 8.2% (1)
- Forecast includes sales of iPill dispenser only. Revenue from the revenue sensor, remote monitoring, data and app subscriptions
- *TAM Total Addressable Market. **SOM Serviceable Obtainable Market

iPill. Competitive Landscape

	Active Control Dispenser	Pill Reminders	Passive Control Dispenser
Opioid Storage	Secured	Not Secured	Not Secured
Safe Disposal	Destroys on tampering Automatically at 90 days	Sometimes	Sometimes
Tamper resistance	Safe	No	No
Opioid Prevention	Yes	No	No
Cognitive behavioral therapy	Integrated	Not Included	Not Included
Monitors respiration	Integrated	No	No
Calls 911	Integrated	No	No
Remote physician access	Integrated	No	Sometimes
Blockchain technology	Yes	No	No


The iPill



iPill Advantage over the Competition

- 1. Secure storage and safe disposal.
- 2. Winner of the 2018 FDA Innovation Challenge for Treatment and Prevention of Opioid Use Disorder.
- 3. Designated as a "Breakthrough" medical device by the FDA.
- 4. Granted *de novo* 510K Class II expedited approval path.
- 5. Eligible for 3 years of market exclusivity through the Hatch-Waxman Act.

iPill... Accomodates Multiple Business Models



The iPill_m Board

Experienced business executives


	Chairman John Hsu MD	
Peter Weinstein, PhD, JD	Sherie Hsieh, BS Co-Founder	Nick Spring
Dr. Weinstein is an IP Attorney and former USPTO Reviewer.	Ms. Hsieh runs an international real estate investment firm.	Mr. Spring has founded and exited from a medical device and a biopharma company

iPill_M Management

		CTO James Yang, BS	CEO John Hsu MD	Manufacturing Tony Chang BS	
Legal	Finance	Marketing	Regulatory	Technology	Medicine
Legal Counsel Contracts	CFO CRO	Consultant Marketing	Regulatory Former CDRH Director	Consultant QMS	1 Consultant Clinical Heads of Major Universities 2 Consultants
Legal Counsel IP	Controller	Consultant Commercialization	Consultant Regulatory	CIO Cybersecurity/HIPPA	
		Consultant Pricing Specialist		Consultant CBT Module	Pharmacy Supply Chain
				Contract Respiratory Sensor	
				Contract Tamper-resistance	
Consultants / Con Available to re-en	-		Contract Hardware design		

Customer Base

iPill_m - 4 Sources of Revenue



iPill. Dispenser Expenditures

<u>Already Done</u>	\$500K spent by founders For proof of concept	<u>To be Done</u>	\$1.5 million request from investors For FDA Registration Class I Approval
	Premarketing to insurers iPill App prototype built		iPill Dispenser Industrial design
	iPill App QMS tested		iPill Dispenser QMS tested iPill App completion
	iPill Dispenser prototype built		iPill App QMS testing
	iPill Dispenser QMS tested		FDA Class I approval
	Granted patent		Injection mold tooling
	FDA registration Class I		Logistics, Distribution, Marketing
	Team assembled not employed		Market Launch
	Customers identified		Personnel Employed

Appendix

iPill_m Next steps for Future investors

- Aug 2019 In 2019 large Canadian pharmacy chain approached iPilltm to be exclusive secure packager
- Dec 2019 FDA Class I Registration of iPill Dispenser (iPilltm Class I - Tamper-resistant design and CBT component)
- Dec 2019 Secure strategic partners / investor commitments
- Mar 2020 Build Business Team
- Apr 2020 Structure Manufacturing (Fortune 100 company has signed a MOU)
- Apr 2020 Structure Supply Chain/Distribution) (2 opioid packagers have signed a MOU)
- Apr 2020 Marketing
- May 2020 Logistics
- Jun 2020 FDA Class I Launch to market
- Future iPill Class II de novo regulatory path (iPilltm Class I also with, bidirectional physician remote access, a biosensor to detect respiratory depression Collection of data for Blockchain

Intellectual Property Summary

- iPill Patent granted on October 1, 2019 as U.S. Patent No. 10,426,707
 - 21 years of IP Protection.
 - 3 years market exclusivity with the Hatch-Waxman Act.
- Trademark iPill, iPill Dispenser, iPill Smart Dispenser.
- www.iPilldispenser.com.

iPill_m Timeline and Milestones

	Today									
	2017	2018	2019	May	June	Sept	Dec	2020	Jan	June
Company history IP Status	Company started	Patent Filed p	Patent oublished	Notice of Patent Allowance		Patent Granted				
Marketing	Clinical S Pilot stuc PBMs/ins	dies with						Clinical St Pilot stud PBMs/ins	ies with	Market Launch
Regulatory status	Protot iPillym A Dispense	.,	2018 Winr tion Challe Use Diso	enge Breakthro	ough	510	De Nov K Class proval	-	FDA De No 510K Class Approva	s II Post Market
Industrial Design							DFX: 3- E [PV ⁻ W	dustrial Design -4wks EVT: 12 wks DVT: 8-12wks T: 4 wks 1P: 2-3 wks pp Design comp	oletion	
Clinical Studies								Clinical	Studies cacy nan	

Who pays for the iPill.?

Goal is to minimize additional patient burden on insurers

Insurers

- Each insured patient who abuses opioids costs the insurer an additional \$14,810 annually.¹
 - iPill can significantly reduce this cost, in part by being granted standard HHS HCPCS Code for insurance reimbursement
 - A similar device, Pacira's Exparel is labeled as an opioid reduction technology.
 - It uses HCPCS² code C9290 for insurance reimbursement
 - The iPill_{tm} value proposition was pre-marketed to OPTUM, ExpressScripts, BlueCross all of which indicated an openness to participate in pilot studies once the FDA IDE is filed.

CMS

- CPT code for physician remote monitoring of chronic pain
 - iPill to bill and collect monthly codes 99190,99090,G2010,G2012.³
- 1. https://www.jmcp.org/doi/full/10.18553/jmcp.2017.16265
- 2. HCPCS Healthcare Common Procedure Code
- 3. <u>https://currenthealth.com/remote-patient-monitoring-reimbursement</u>

iPill Team

CEO Cofounder

John Hsu MD was an anesthesiologist and pain management physician for 28 years. <u>Software Engineer for Mobile App and Blockchain</u> <u>James Yang</u> BS was the principal developer for Ticketmaster and Hilton Hotel Mobile app.

Manufacturing & Supply Chain Consultant

Tony Chang, BS, worked as sales director for Ennoconn corporation He discovered 2 companies that recently sold to Amazon for more than \$1 billion.

Science Advisory Board

Scientific Advisor

Daniel I. Sessler, MD, Professor Cleveland Clinic

Dr. Sessler was the Editor, *Anesthesiology* and Seven other editorial boards in 2012. He has authored more than 750 full research papers; including 12 in the *New England Journal of Medicine*, 6 in *The Lancet*, and more than 200 in *Anesthesiology*.

Scientific regulatory advisor

Brian Harvey MD, PhD, former CDRH director of the FDA and is an expert on regulatory affairs for biologics, drugs, and medical device development programs.

Software engineer cognitive behavioral therapy module Jared Adams, MD, PhD.

Dr. Adams is the CMO, CSO and director of research and product development of Self Care Catalyst, which currently has 60,000 users.

Pharmacy Supply Chain and Manufacturing Consultant

FDA Pharmacy Regulatory Consultant

Robert Nickell, RPh. as Associate Professor of Pharmacy taught FDA pharmacy regulations at the University of Southern California the Pharmacy School.

Consultants / Contractors

Legal counsel

Peter Weinstein PhD, JD, is a former USPTO reviewer and senior Patent Counsel at Baxter Healthcare Corporation. He was responsible for managing legal and intellectual property matters for Baxter.

Consultant Pharmaceutical Distribution and Operations

Christian Baker, MBA, has more than 25 years' experience working in operations, finance and distribution within the healthcare and pharmaceutical industry, mostly at McKesson. He has led large-scale finance and accounting operations managing over \$200B in healthcare-related financial transactions annually.

Consultant Cybersecurity HIPAA Compliance.

Matthew Clark, BS, has a 19-year history of experience in Information Systems Management. As an expert on cybersecurity, HIPAA, compliance, and information systems management, and has been awarded nearly \$400 million in multiple NIH, DOD, and HHS grants.

Consultant Commercial Officer

Chris Buckley, BA, has long been a successful marketing and commercialization executive in the medical device sector, specifically drug dispensers. He worked for 15 years at Pyxis, the hospital version of an automatic pill dispenser and Livi, a home pill reminder for the elderly.

Consultant Corporate Finance

Lacarya Scott, MBA has 16 years' experience across life science research, life science buy-side and biopharmaceutical companies advising on M&A transactions.

Consultant FDA Regulatory

Ginger Cantor, MBA, is a certified Regulatory Affairs/Quality professional with 25 years' experience, mostly at 3M. She has focused on pharmaceuticals, medical devices, and biological products)

Consultant Quality Systems Management

Kyle Rose, MBA, is a medical Device expert and a certified quality auditor (CQA) with regulatory and submission experience for a variety of markets including FDA, CE Mark, Health Canada, and CFDA.

Consultant Engineer for the iPill Dispenser Hardware

Nisha Sawhney, M. Arch. is an expert in industrial Design who specializes in mechanical design and engineering, medical device manufacturing and IOT connected devices.

Consultant Hardware Engineer for the Respiratory Sensor

Alfonso Limon PhD, is a technical director with numerous medical device engineering designs and medical applications combining mathematics, physics and machine learning.